BIENAIME JEAN JACQUES
Transaction: 07/15/2026
BUY
Change
+1,000
Price
$10.61
Filing
07/17/2026
Type
BUY
Keros Therapeutics, Inc.
KROS • Biotechnology
$11.32
▲ +0.21 (+1.89%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$327.98M
Growth
28.6%
Cash Flow
1/5
Trend
Volatile
Evidence
Stable or improving margins · 35.7%Positive revenue growth · 66.1%Positive free cash flow · 2.85Reasonable earnings multiple · 8.71Manageable debt level · 0.06
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$11.32
Change1.89%
Market Cap$327.98M
52W Range9.69 - 22.55
Beta1.01
Dividend Yield0.00%
Gross Margin99.38%
Oper. Margin28.94%
Profit Margin35.65%
Debt/Eq0.06
Current Ratio15.45
Quick Ratio15.45
Price$11.32
Change1.89%
Market Cap$327.98M
52W Range9.69 - 22.55
Beta1.01
Dividend Yield0.00%
Gross Margin99.38%
Oper. Margin28.94%
Profit Margin35.65%
Debt/Eq0.06
Current Ratio15.45
Quick Ratio15.45
Revenue 5Y28.62%
FCF 5Y20.57%
Target$20.33
Target Upside79.59%
Target Median$20.00
Target Range18.00 - 23.00
Volume276.93K
Avg Volume285.07K
EPS Surprise-0.29
Investment DNA
How strong this company looks for long-term investors
82
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
88/100
Why this score▼
Stable or improving margins · 35.7%Positive revenue growth · 66.1%Positive free cash flow · 2.85Reasonable earnings multiple · 8.71Manageable debt level · 0.06Healthy liquidity · 15.45
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 17 analyst votes · 2026-09-05
79/100
Bullish
Bullish
10
Hold
7
Bearish
0
Price Target
2026-08-05
Low
$18.00
Mean
$20.33
Median
$20.00
High
$23.00
Insider Transactions
Recent executive and insider activity
Prener Anne
Transaction: 07/01/2026
OTHER
Change
0
Price
Not reported
Filing
07/06/2026
Type
OTHER
Prener Anne
Transaction: 07/01/2026
BUY
Change
+13,786
Price
Not reported
Filing
07/06/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | BUY | +1,000 | $10.61 | 07/15/2026 | 07/17/2026 |
| Prener Anne | OTHER | 0 | Not reported | 07/01/2026 | 07/06/2026 |
| Prener Anne | BUY | +13,786 | Not reported | 07/01/2026 | 07/06/2026 |
| Prener Anne | BUY | +14,870 | $10.88 | 07/01/2026 | 07/06/2026 |
| BIENAIME JEAN JACQUES | BUY | +1,000 | $10.19 | 06/15/2026 | 06/17/2026 |
| Newton Charles W. | SELL | -550 | $10.04 | 06/11/2026 | 06/15/2026 |
| Knowles Julius | SELL | -2,625 | $10.73 | 06/04/2026 | 06/08/2026 |
| Farzan Nima | SELL | -2,625 | $10.73 | 06/04/2026 | 06/08/2026 |
| Seth Alpna | SELL | -2,625 | $10.72 | 06/04/2026 | 06/05/2026 |
| Knowles Julius | BUY | +7,433 | $10.50 | 06/03/2026 | 06/05/2026 |
| Knowles Julius | BUY | +7,142 | Not reported | 06/03/2026 | 06/05/2026 |
| BIENAIME JEAN JACQUES | BUY | +7,433 | $10.50 | 06/03/2026 | 06/05/2026 |
| BIENAIME JEAN JACQUES | BUY | +7,142 | Not reported | 06/03/2026 | 06/05/2026 |
| Farzan Nima | BUY | +7,433 | $10.50 | 06/03/2026 | 06/05/2026 |
| Farzan Nima | BUY | +7,142 | Not reported | 06/03/2026 | 06/05/2026 |
| GRAY MARY ANN | BUY | +7,433 | $10.50 | 06/03/2026 | 06/05/2026 |
| GRAY MARY ANN | BUY | +7,142 | Not reported | 06/03/2026 | 06/05/2026 |
| Seth Alpna | BUY | +7,433 | $10.50 | 06/03/2026 | 06/05/2026 |
| Seth Alpna | BUY | +7,142 | Not reported | 06/03/2026 | 06/05/2026 |
| BIENAIME JEAN JACQUES | BUY | +1,000 | $10.58 | 05/15/2026 | 05/19/2026 |